HOME >> BIOLOGY >> NEWS
U.S.-German research consortium sequences genome of versatile soil microbe

including phenylalkanoates, ferulate, vanillate, and coniferyl- and coumaryl alcohols, aldehydes and acids. TIGR Assistant Investigator Ian Paulsen, who explored the correlation of metabolic pathways with membrane transport capability, said P. putida has "lots of novel pathways and transport capabilities to break down aromatic and other unusual compounds."

The P. putida genome also was compared to that of other species to reveal details about the microbe's evolutionary history. Perhaps the most revealing comparison was with the genome of another member of the Pseudomonas genus P. aeruginosa, which is an opportunistic pathogen and the leading cause of death for cystic fibrosis patients.

TIGR evolutionary biologist Jonathan Eisen said, "Such comparisons among closely related species with different biological properties are invaluable in learning about the biology of each species. In this case it allows us to better identify the features in the P. aeruginosa genome that contribute to making it a pathogen."

An analysis by Tuemmler and Christian Weinel of the MHH identified numerous chemosensory systems, cell attachment factors, and transport systems in P. putida that had been thought to be involved in virulence in P. aeruginosa. For example the KT2440 (P. putida) genome contains a chromosomal region that is present in 85% of P. aeruginosa clinical isolates from sepsis and urinary tract infections. "That suggests that those genes many not be specific for virulence," said Eisen. The researchers did, however, find many genes in P. aeruginosa and not P. putida that had not previously been identified as candidates for being involved in pathogenicity. The identification of such genes may help biomedical researchers pinpoint potential targets for developing drugs or vaccines against this pathogen.


'"/>

Contact: Robert Koenig
rkoenig@tigr.org
301-838-5880
The Institute for Genomic Research
2-Dec-2002


Page: 1 2 3

Related biology news :

1. Leader in cancer treatment and prevention research honored
2. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative
3. Scientists to prototype cyberinfrastructure for research and education access to ocean observatories
4. Belgian researchers explore revolutionary approach to angiogenesis
5. Award winning researchers reveal potential new role for Glivec
6. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
7. 16 APS exercise research highlights, from reduced flu mortality to proteomics & obesity
8. Gene chips research in cotton could lead to superior variety
9. Groundbreaking research could ignite new solutions to heat transfer in nano-devices
10. New hydrothermal vents discovered as South Pacific Odyssey research begins
11. University of Alberta researcher looks for clues to mysterious disease

Post Your Comments:
(Date:5/14/2015)... May 14, 2015  Verificient Technologies, Inc., ... and online remote proctoring, announced a new ... company and creator of the Canvas Learning ... two companies will benefit from the seamless ... As a fully integrated multifactor biometrics ...
(Date:5/11/2015)... Ohio , May 11, 2015  Through a well-rounded ... Ohio had a strong showing at AUVSI,s Unmanned ... These representatives of Ohio,s UAS industry ... and abroad from all points along the UAS ecosystem. ... Development Coalition,s (DDC) Vice President for Aerospace Rich Knoll ...
(Date:5/10/2015)... GOTHENBURG, Sweden , May 11, 2015 ... touch fingerprint sensors FPC1025 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... the sensors will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + 1 000 ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
(Date:5/21/2015)... Specialty Pharmacy Times has completed its ... BPA Worldwide as a business publication member. As ... for Specialty Pharmacy Times based on business/distribution, demographics ... member of BPA Worldwide, Specialty Pharmacy Times shows ... the most reliable, unequaled data,” said Chris Hennessy, ...
(Date:5/21/2015)... 21, 2015  The EveryLife Foundation for Rare ... and Amy Klobuchar (D-MN) today for ... & Treatments, or OPEN ACT. Supported ... organizations, this bipartisan legislation promises to rapidly bring ... rare disease patients by incentivizing drug makers to ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Veolia’s environmental monitoring technology division, ... distribution agreement with VWR to distribute TECTA™ B16, ... than 160 years of experience, VWR, a leading ... and production facilities, has cultivated a value proposition ... to enable science. Endetec’s TECTA™ B16, combines ...
Breaking Biology Technology:Specialty Pharmacy Times Joins BPA Worldwide 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
Cached News: